Innovative drugs surge: Is earnings growth driving a sector value revaluation?
Innovative drugs surge: Is earnings growth driving a sector value revaluation? Today, Hong Kong-listed innovative drug stocks rallied sharply, with WuXi XDC soaring over 14%, Asymchem jumping 16.83%, and Insilico Medicine rising 12.87%. On the news front, WuXi XDC and Asymchem just released their interim 2026 results. For WuXi XDC, first-half revenue reached RMB 3.701 billion, up 37.0% year-on-year, in line with market expectations; net profit attributable to shareholders was RMB 819 million, up 9.9%; adjusted net profit attributable to shareholders was RMB 1.027 billion, up 37.4%, essentially matching revenue growth and indicating sound earnings quality. Gross margin was 37.0%, up 0.9 percentage points year-on-year. Order backlog remained robust, with unfilled service orders of approximat
Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company mainly engaged in the research, development, production and sales of drugs. The Company focuses on the field of oncology, covering kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, hormone receptor regulation, deoxyribonucleic acid (DNA) repair and epigenetics, supportive care and other research areas. The Company's products include anti-tumor, analgesic anesthesia and contrast agents, which are used in autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, blood diseases, pain management, neurological diseases, ophthalmology, nephrology and other fields. The Company mainly conducts its businesses in domestic and foreign markets.